#	Pagina
attuale pagina	/open-h2020/projects/211033/index.html

Opendata, web and dolomites

NOVITREP

Novel viral therapy through targeting DNA repair

Total Cost €

EC-Contrib. €

Partnership

Views

NOVITREP project word cloud

Explore the words cloud of the NOVITREP project. It provides you a very rough idea of what is the project "NOVITREP" about.

proof resistance income constant infectious proteins born drug investigation foundation causal zikv damage cancer inhibitors cchfv repair business pathogenic zoonotic host world tool threatening life viral cycle disturbs hemorrhagic cell demonstrating western revealed health prevented human potent zika networks genecadd therapeutics market surprise internationally ebola prevent therapy therapeutic optimize grant agency genetic public perform exists secure oxidative viruses rna ip outbreak pose epidemics fever action discover individuals acquired congo relationship suggesting causing dna erc company newly replication explore anti therapies outbreaks sweden power babies cells global strategy antiviral plan reduce ebov battle diseases mechanism infected potently made lesions ongoing natural crimean treatments virus microcephaly

Project "NOVITREP" data sheet

The following table provides information about the project.

Coordinator	KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2016-PoC
Funding Scheme	ERC-POC
Starting year	2017
Duration (year-month-day)	from 2017-07-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	coordinator	139˙162.00
2	KAROLINSKA INSTITUTET INNOVATIONS AB KAROLINSKA INSTITUTET INNOVATIONS AB Organization address address: TOMTEBODAVAGEN 23 A city: SOLNA postcode: 171 65 website: www.karolinskainnovations.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SOLNA)	participant	10˙837.00

Map

Project objective

Natural epidemics and outbreaks of emerging infectious diseases are a growing problem internationally. RNA viruses remain under constant attention due to the recent Zika virus (ZIKV) outbreak with potential causal relationship with microcephaly of newly born babies and Ebola virus (EBOV) and Crimean-Congo hemorrhagic fever virus (CCHFV) causing life threatening hemorrhagic fever, demonstrating how zoonotic viruses pose a major global health concern. There is an ongoing need to discover novel therapies to battle these pathogenic viruses given that no specific therapy exists. Developing new antiviral treatments by targeting host cell proteins needed in the viral life cycle is an emerging strategy to improve therapeutic power and reduce acquired drug resistance.

Based on the results from the ERC grant Genetic Networks as a tool for anti-Cancer Drug Development (GENECADD), we have developed potent inhibitors to DNA repair proteins that disturbs repair of oxidative DNA lesions. To our surprise, we observed, in collaboration with Public Health Agency of Sweden, that these inhibitors potently prevent ZIKV, EBOV and CCHFV viral replication in human cells, suggesting that these inhibitors may be used as antiviral therapeutics. Further investigation into the possible mechanism of action revealed that our inhibitors prevented the repair of oxidative damage to RNA.

Here, the overall aim is to (1) further develop and optimize our inhibitors as a novel antiviral target and demonstrate proof of concept, (2) explore and secure IP (3) develop a business plan and (4) perform a market analysis. The overall goal is to develop general antiviral treatments made available to virus-infected individuals through a public foundation in low-income areas or through a company in the Western world.

Publications

List of publications.
year	authors and title	journal	last update
2018	Torkild Visnes, Armando CÃ¡zares-KÃ¶rner, Wenjing Hao, Olov Wallner, Geoffrey Masuyer, Olga Loseva, Oliver Mortusewicz, ElisÃ©e Wiita, Antonio Sarno, Aleksandr Manoilov, Juan Astorga-Wells, Ann-Sofie Jemth, Lang Pan, Kumar Sanjiv, Stella Karsten, Camilla Gokturk, Maurice Grube, Evert J. Homan, Bishoy M. F. Hanna, Cynthia B. J. Paulin, Therese Pham, Azita Rasti, Ulrika Warpman Berglund, Catharina von Nicolai, Carlos Benitez-Buelga, Tobias Koolmeister, Dag Ivanic, Petar Iliev, Martin Scobie, Hans E. Krokan, Pawel Baranczewski, Per Artursson, Mikael Altun, Annika Jenmalm Jensen, Christina KalderÃ©n, Xueqing Ba, Roman A. Zubarev, PÃ¥l Stenmark, Istvan Boldogh, Thomas Helleday Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation published pages: 834-839, ISSN: 0036-8075, DOI: 10.1126/science.aar8048	Science 362/6416	2019-09-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVITREP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVITREP" are provided by the European Opendata Portal: CORDIS opendata.